NRAS and melanoma: In addition, immune checkpoint inhibitors have been shown to significantly improve melanoma patient survival, and it is notable that better response rates to immune checkpoint inhibitors have been reported in melanomas with high mutation loads, particularly those containing NRAS mutations [13].